Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...
Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...
The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...
Facephi achieves outstanding results in RIVTD Track 3 Evaluation from Department of Homeland Security (DHS)1 in the USA This evaluation assessed the accuracy and robustness of biometric authentication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback